BioSpace News Archive

An oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide

Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the phase 2 pilot 2-THE-TOP trial testing the safety and efficacy of Tumor Treating Fields

Abeona Therapeutics Inc. today announced financial results for the third quarter 2021 and recent business progress.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that, on November 9, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 80,000 shares of common stock and 30,000 restricted stock unit awards to two employees who have recently joined HTG.

Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins, reported financial results and provided a business update for the quarter ended September 30, 2021.

Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented by Intensity Therapeutics during the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and the Connective Tissue Oncology Society (CTOS) Annual Meeting

Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22.

AcelRx Pharmaceuticals, Inc. announced the execution of a definitive merger agreement to acquire Lowell Therapeutics, Inc., a privately held company, and reported its third quarter 2021 financial results.

DarioHealth Corp. today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer

NanoViricides, Inc. announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients.